Advertisement
INCY or PFE or ZTS
Which Stock Would AI Choose? Incyte Corporation (INCY) vs. Pfizer Inc. (PFE) vs. Zoetis Inc. (ZTS) Stock Comparison
Key Takeaways
- INCY leads with 52% one-year gains and attractive 14.7x P/E, bolstered by recent EU approvals for oncology drugs like Zynyz.
- PFE tops YTD performance at 12%, trading at a forward P/E of 9.3x amid promising oncology pipeline data.
- ZTS lags with YTD and one-year declines, pressured by reduced guidance on Librela safety issues in animal health.
- INCY and PFE show stronger momentum in biotech/pharma relative to ZTS's recent weakness.
- Valuation favors INCY on PEG (0.32) and relative affordability versus peers.
Introduction
This stock comparison examines INCY, a biopharmaceutical focused on oncology and inflammation; PFE, a diversified pharma giant with broad therapeutic exposure; and ZTS, the leader in animal health medicines and vaccines. Traders seeking sector-specific plays in biotech, large-cap pharma, or resilient animal health may find value in analyzing their relative performance, valuations, and recent catalysts. Amid shifting market sentiment in healthcare, understanding price behavior, momentum, and growth drivers aids informed positioning in this volatile space.
INCY Overview and Recent Performance
Incyte Corporation (INCY) is a biopharmaceutical firm specializing in oncology, hematology, and inflammation therapeutics, with key products like Jakafi, Opzelura, and expanding labels for Zynyz and Minjuvi. In recent market activity, shares trade around $94, up 52% over the past year but down modestly YTD amid post-earnings pressure. Q4 2025 revenue beat estimates at $1.51 billion, driven by strong Jakafi and Opzelura sales, though EPS missed due to higher expenses. Sentiment has lifted on EU approvals for Zynyz in anal cancer and Minjuvi expansions in Latin America, signaling pipeline diversification ahead of Jakafi patent cliffs. With a 14.7x trailing P/E and beta of 0.84, INCY reflects relative stability in biotech volatility.
PFE Overview and Recent Performance
Pfizer Inc. (PFE) develops and markets biopharmaceuticals across oncology, vaccines, rare diseases, and inflammation, featuring blockbusters like Eliquis, Prevnar, and Ibrance. Shares hover near $27.50, with solid YTD gains of 12% and 13% one-year rise, supported by a low beta of 0.41 for defensive appeal. Recent weeks highlight positive phase 2 data for CDK4 inhibitor atirmociclib in breast cancer, offsetting vaccine segment scrutiny. Trading at 20.2x trailing P/E but a compelling forward 9.3x, PFE benefits from pipeline momentum and high dividend yield, though earnings pressures persist in a post-COVID landscape.
ZTS Overview and Recent Performance
Zoetis Inc. (ZTS) leads animal health with vaccines, parasiticide, dermatology, and diagnostics for companion and livestock animals. Shares at about $122 have declined YTD and 25% over the past year, with recent weakness accelerating on lowered full-year guidance due to Librela osteoarthritis therapy safety concerns. Despite Q4 revenue growth to $2.4 billion and EPS beats, companion animal softness weighs on sentiment. At 20.2x P/E and beta near 1, ZTS trades at a premium on price/sales (5.7x) but shows vulnerability in sector-specific headwinds.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the platform's top-performing AI trading bots, curated from hundreds available that trade thousands of tickers across diverse strategies. Only the most suitable for prevailing market conditions earn a spot in this dynamic section, where AI continuously analyzes all 351+ bots to spotlight 25 trending ones in high-growth sectors. These include signal agents for real-time trades, virtual agents with risk controls, and brokerage agents, spanning timeframes like 5min to 60min and styles from technical to fundamental. Past highlights show annualized returns up to 279% with win rates over 90% on select ETFs and stocks, underscoring adaptive performance in volatile environments. Explore these bots to align with your trading timeframe and risk profile.
Head-to-Head Comparison
INCY’s oncology focus contrasts PFE’s diversified pharma model and ZTS’s animal health niche, with biotech growth drivers for INCY versus PFE’s scale and ZTS’s steady livestock demand. Recent momentum favors INCY (52% 1Y) over PFE (13%) and lagging ZTS (-25%). Risks include INCY’s patent exposures, PFE’s vaccine declines, and ZTS’s product-specific setbacks. Valuation sensitivity shows INCY cheapest at 14.5x P/E and low PEG, PFE attractive forward (9x), while ZTS premiums on book value. Market sentiment tilts positive for human health amid regulatory wins, versus animal sector caution.
Tickeron AI Verdict
Tickeron’s AI currently leans toward INCY based on superior trend consistency, attractive relative valuation, and oncology catalysts positioning it ahead in biotech momentum. PFE offers stability with pipeline progress, while ZTS trails on recent downgrades. Observable factors suggest higher probability of outperformance for INCY in the near term, though sector rotations could shift dynamics.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
INCY’s FA Score shows that 1 FA rating(s) are green whilePFE’s FA Score has 1 green FA rating(s), and ZTS’s FA Score reflects 2 green FA rating(s).
- INCY’s FA Score: 1 green, 4 red.
- PFE’s FA Score: 1 green, 4 red.
- ZTS’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
INCY’s TA Score shows that 5 TA indicator(s) are bullish while PFE’s TA Score has 4 bullish TA indicator(s), and ZTS’s TA Score reflects 5 bullish TA indicator(s).
- INCY’s TA Score: 5 bullish, 4 bearish.
- PFE’s TA Score: 4 bullish, 4 bearish.
- ZTS’s TA Score: 5 bullish, 4 bearish.
Price Growth
INCY (@Biotechnology) experienced а +1.82% price change this week, while PFE (@Pharmaceuticals: Major) price change was +2.38% , and ZTS (@Pharmaceuticals: Generic) price fluctuated +3.84% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +7.61%. For the same industry, the average monthly price growth was +9.02%, and the average quarterly price growth was +11.47%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.21%. For the same industry, the average monthly price growth was +2.48%, and the average quarterly price growth was +7.89%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +3.70%. For the same industry, the average monthly price growth was +8.17%, and the average quarterly price growth was +2.15%.
Reported Earning Dates
INCY is expected to report earnings on Apr 28, 2026.
PFE is expected to report earnings on May 05, 2026.
ZTS is expected to report earnings on May 07, 2026.
Industries' Descriptions
@Biotechnology (+7.61% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Pharmaceuticals: Major (+1.21% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
@Pharmaceuticals: Generic (+3.70% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
| INCY | PFE | ZTS | |
| Capitalization | 19.5B | 157B | 51.5B |
| EBITDA | 1.76B | 16.8B | 4.07B |
| Gain YTD | -0.962 | 12.537 | -2.319 |
| P/E Ratio | 15.26 | 20.26 | 20.33 |
| Revenue | 5.14B | 62.6B | 9.47B |
| Total Cash | 3.58B | 13.6B | 2.31B |
| Total Debt | 40.4M | 64B | 9.24B |
INCY | PFE | ZTS | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 78 | 84 | 9 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 69 Overvalued | 34 Fair valued | 30 Undervalued | |
PROFIT vs RISK RATING 1..100 | 72 | 100 | 100 | |
SMR RATING 1..100 | 32 | 74 | 16 | |
PRICE GROWTH RATING 1..100 | 47 | 27 | 60 | |
P/E GROWTH RATING 1..100 | 100 | 34 | 85 | |
SEASONALITY SCORE 1..100 | 50 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ZTS's Valuation (30) in the Pharmaceuticals Generic industry is in the same range as PFE (34) in the Pharmaceuticals Major industry, and is somewhat better than the same rating for INCY (69) in the Biotechnology industry. This means that ZTS's stock grew similarly to PFE’s and somewhat faster than INCY’s over the last 12 months.
INCY's Profit vs Risk Rating (72) in the Biotechnology industry is in the same range as ZTS (100) in the Pharmaceuticals Generic industry, and is in the same range as PFE (100) in the Pharmaceuticals Major industry. This means that INCY's stock grew similarly to ZTS’s and similarly to PFE’s over the last 12 months.
ZTS's SMR Rating (16) in the Pharmaceuticals Generic industry is in the same range as INCY (32) in the Biotechnology industry, and is somewhat better than the same rating for PFE (74) in the Pharmaceuticals Major industry. This means that ZTS's stock grew similarly to INCY’s and somewhat faster than PFE’s over the last 12 months.
PFE's Price Growth Rating (27) in the Pharmaceuticals Major industry is in the same range as INCY (47) in the Biotechnology industry, and is somewhat better than the same rating for ZTS (60) in the Pharmaceuticals Generic industry. This means that PFE's stock grew similarly to INCY’s and somewhat faster than ZTS’s over the last 12 months.
PFE's P/E Growth Rating (34) in the Pharmaceuticals Major industry is somewhat better than the same rating for ZTS (85) in the Pharmaceuticals Generic industry, and is significantly better than the same rating for INCY (100) in the Biotechnology industry. This means that PFE's stock grew somewhat faster than ZTS’s and significantly faster than INCY’s over the last 12 months.
| INCY | PFE | ZTS | |
|---|---|---|---|
| RSI ODDS (%) | 3 days ago 63% | N/A | 4 days ago 52% |
| Stochastic ODDS (%) | 3 days ago 57% | 3 days ago 66% | 3 days ago 62% |
| Momentum ODDS (%) | 3 days ago 63% | 3 days ago 51% | 3 days ago 61% |
| MACD ODDS (%) | 3 days ago 67% | 3 days ago 55% | 3 days ago 65% |
| TrendWeek ODDS (%) | 3 days ago 63% | 3 days ago 55% | 3 days ago 56% |
| TrendMonth ODDS (%) | 3 days ago 60% | 3 days ago 51% | 3 days ago 54% |
| Advances ODDS (%) | 11 days ago 61% | 3 days ago 56% | 6 days ago 52% |
| Declines ODDS (%) | 4 days ago 60% | 10 days ago 57% | 4 days ago 58% |
| BollingerBands ODDS (%) | 3 days ago 67% | 3 days ago 52% | 3 days ago 62% |
| Aroon ODDS (%) | 3 days ago 60% | 3 days ago 52% | 3 days ago 61% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| BETE | 38.53 | 1.08 | +2.89% |
| ProShares Bitcoin & Eth Eq Wgh ETF | |||
| DFSV | 37.05 | 0.58 | +1.59% |
| Dimensional US Small Cap Value ETF | |||
| ENHU | 26.36 | 0.32 | +1.22% |
| iShares Enhanced Large Cap Core Actv ETF | |||
| SFEB | 25.15 | 0.28 | +1.13% |
| FT Vest U.S. Small Cap Mod Buf ETF-Feb | |||
| EIM | 9.89 | 0.02 | +0.22% |
| Eaton Vance Municipal | |||
INCY and
Correlation & Price change
A.I.dvisor indicates that over the last year, INCY has been loosely correlated with BMRN. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if INCY jumps, then BMRN could also see price increases.
| Ticker / NAME | Correlation To INCY | 1D Price Change % | ||
|---|---|---|---|---|
| INCY | 100% | +2.62% | ||
| BMRN - INCY | 43% Loosely correlated | +1.00% | ||
| PTCT - INCY | 41% Loosely correlated | +1.02% | ||
| GMAB - INCY | 40% Loosely correlated | +0.88% | ||
| TECH - INCY | 39% Loosely correlated | +3.26% | ||
| AXON - INCY | 39% Loosely correlated | +2.49% | ||
More | ||||
PFE and
Correlation & Price change
A.I.dvisor indicates that over the last year, PFE has been loosely correlated with MRK. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is some statistical probability that if PFE jumps, then MRK could also see price increases.
| Ticker / NAME | Correlation To PFE | 1D Price Change % | ||
|---|---|---|---|---|
| PFE | 100% | +1.25% | ||
| MRK - PFE | 66% Loosely correlated | +3.13% | ||
| BMY - PFE | 64% Loosely correlated | +2.05% | ||
| BIIB - PFE | 61% Loosely correlated | +0.76% | ||
| AMGN - PFE | 58% Loosely correlated | +1.69% | ||
| NVS - PFE | 54% Loosely correlated | +1.50% | ||
More | ||||
ZTS and
Correlation & Price change
A.I.dvisor indicates that over the last year, ZTS has been loosely correlated with ELAN. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if ZTS jumps, then ELAN could also see price increases.
| Ticker / NAME | Correlation To ZTS | 1D Price Change % | ||
|---|---|---|---|---|
| ZTS | 100% | +2.81% | ||
| ELAN - ZTS | 46% Loosely correlated | +2.38% | ||
| PRGO - ZTS | 38% Loosely correlated | +3.33% | ||
| VTRS - ZTS | 37% Loosely correlated | +4.78% | ||
| HLN - ZTS | 37% Loosely correlated | +1.67% | ||
| PAHC - ZTS | 36% Loosely correlated | +5.92% | ||
More | ||||